

RedChip Group Investor Webinar

December 2023

Forward-looking statements

This presentation contains statements about BioVie's future expectations, plans, strategies and prospects which constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 BioVie has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Forward-looking statements are subject to risks, uncertainties and assumptions that could cause BioVie's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are: the Company's ability to raise the substantial capital needed to fund its operations and research and development; risks associated with clinical development and the Company's ability to successfully complete pre-clinical and clinical testing and be granted regulatory approval for its products to be sold and marketed in the United States or elsewhere; the Company's reliance on third parties to conduct its clinical trials and manufacture its product candidates; the Company's ability to establish and/or maintain intellectual property rights covering its product candidates; competition; and other risks described in greater detail in the Company's filings with the Securities and Exchange Commission (the "SEC"). In addition to the risks described above and in BioVie's filings with the SEC, other unknown or unpredictable factors also could affect BioVie's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. You should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date that these slides are posted to BioVie's website or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Overview

- NE3107 appears to be biologically active
- Cognitive, functional, biomarker efficacy signal suggest that NE3107:
 - Has a treatment advantage equal to or greater than results reported from clinical trials from approved monoclonal antibody treatments;
 - Associated with a benign safety profile
- Unanticipated exclusion of sites due to deviations led to study being underpowered. Adaptive feature of trial allows the Company to continue enrolling patients to reach statistical significance

Week 30 Suggest NE3107 Advantage vs. Placebo is Comparable to or Better than Results Reported from Clinical Trials by Approved Medications


	Placebo Decline	NE3107	NE3107 vs. Placebo	Comparator (18 mos)
CDR-SB	+1.39	+0.44	-0.95 (68%)	-0.45 (27%) ¹
(lower is improvement)	(p=0.0125; n=26)	(p=0.4522; n=24)	(p=0.2278)	-0.39 (22%) ²
ADAS-Cog12	+3.64	+2.70	-0.94 (26%)	-1.44 (25%) ¹
(lower is improvement)	(p=0.0545; n=23)	(p=0.1618; n=24)	(p=0.7212)	-1.40 (27%) ²
MMSE	- 2.54	-1.52	+1.02 (40%)	+0.6 (18%) ²
(higher is improvement)	(p=0.0007; n=26)	(p=0.0547; n=24)	(p=0.3181)	
ADCS-ADL	- 6.54	- 3.46	+3.08 (47%)	+2.0 (36%)1
(higher is improvement)	(p<0.0001; n=27)	(p=0.0435; n=24)	(p=0.1620)	
ADCS-CGIC	+0.31	-0.12	-0.43 (139%)	
(lower is improvement)	(p=0.2733; n=26)	(p=0.6951; n=24)	(p=0.2866)	
ADCOMS	+0.11	+0.09	-0.03 (27%)	-0.05 (23%) ¹
(lower is improvement)	(p=0.0358; n=22)	(p=0.1094; n=24)	(p=0.7063)	

Change from baseline


¹ Lecanamab after 18 months; van Dyck et al. *N Engl J Med* 2023;388:9-2

² Aducunumab after 18 months; Haeberlein et al. J Prev Alz Dis 2022;2(9):197-210

NE3107-treated Patients' Changes in CDR-SB Appears Correlated with Key Biomarkers



NE3107 Appears to Decrease the Neuroinflammatory Processes that Link Nf-L and GFAP to Cognitive Decline




©2023 BioVie Inc. | Corporate presentation 6

biovie

GFAP = Glial fibrillary acidic protein

NE3107-treated Patients Experienced Significant "Age Deceleration" in a Manner Correlated to Cognitive and Functional Improvements

Age Deceleration¹ is used by longevity researchers² to measure the difference between a person's10 - 1biological age and the actual chronological age.




Questions We Have Been Asked


- When did we know that the initial 6 sites need to be excluded? The additional 9 sites?
- What data did we exclude from what was presented at CTAD?
 - Why didn't we exclude data from all 15 sites?
 - Did we knowingly present suspected data to pump the stock price?
- What's the difference between MITT vs. Per-Protocol populations? Why exclude more patients? Are we excluding certain data points and cherry-picking patients to show the best data?
- How can we be certain data from the 57 patients are valid?
- Is there a conspiracy to sabotage this trial?
- Will we identify the 15 sites and the geographic area? The demographic group?
- How can we prevent this from happening again?

Timeline

biovie



Data From All Sites In One Geographic Area Had Data Unlike All Other Sites



Recap

- NE3107 appears to be biologically active
- Cognitive, functional, biomarker efficacy signal suggest that NE3107:
 - Has a treatment advantage equal to or greater than results reported from clinical trials from approved monoclonal antibody treatments;
 - Associated with a benign safety profile
- Unanticipated exclusion of sites due to deviations led to study being underpowered. Adaptive feature of trial allows the Company to continue enrolling patients to reach statistical significance

biovie

Thank You